<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Loibl, Sibylle</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Neoadjuvant Chemotherapy in Women 35 and Under</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Evidence suggests that breast cancer in younger women may be clinically and etiologically distinct from older women [Bleyer A et al. Nat Rev Cancer 2010]. Breast cancer in young women demonstrates a worse prognosis and a more aggressive phenotype, higher proportions of high-grade and later-stage tumors, lower estrogen receptor positivity, and, in some studies, higher expression of human epidermal growth factor receptor 2 [Bleyer A et al. Nat Rev Cancer 2010; Gnerlich JL et al. J Am Coll Surg 2009]. This article presents data on the response to neoadjuvant chemotherapy in women with breast cancer who are aged =35 years compared with older women.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>